Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

Chronic Anemia Cured by Gene Therapy Using Genetically Engineered Blood Vessels

By BiotechDaily International staff writers
Posted on 29 Nov 2011
Print article
A novel gene therapeutic method employing genetically engineered blood vessels to deliver erythropoietin (EPO) to anemic mice was described in a proof-of-concept study.

Investigators at Harvard Medical School (Boston, MA, USA) created a new type of blood vessel by isolating endothelial colony-forming cells from human blood and then inserting into these cells the gene that encodes EPO. The gene that was inserted was part of a complex that included an “off/on switch” activated by the drug doxycycline.

The genetically engineered colony-forming cells were injected under the skin of immunodeficient mice that had been rendered anemic by radiation treatment (as often occurs in cancer patients) or through loss of kidney tissue (modeling chronic kidney failure).

Results published in the November 17, 2011, issue of the journal Blood revealed that the transplanted cells spontaneously formed networks of blood vessels that became integrated into the animals' own circulatory system. EPO produced by the genetically engineered cells was then released directly into the bloodstream. EPO production could be controlled by administrating or withholding doxycycline.

“Blood-vessel implants are an ideal platform technology for gene therapy applications whose goal is systemic drug delivery,” said senior author Dr. Juan M. Melero-Martin, assistant professor of surgery at Harvard Medical School. “Blood vessels are one of the few tissues where we have good control over engraftment. Endothelial cells are easily isolated from blood, are good at assembling themselves into blood vessels, and are ideal for releasing compounds into the bloodstream, since they line the blood vessels.”

“Such drugs are currently made in bioreactors by engineered cells, and are very expensive to make in large amounts. The paradigm shift here is, why we do not instruct your own cells to be the factory?” said Dr. Melero-Martin.

If this approach can be applied in humans, it would relieve patients from having to receive frequent EPO injections, thus reducing the medical costs associated with the management of anemia.

Related Links:
Harvard Medical School


Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

DNA Synthesis Specialists Acquire Advanced Software Design Capabilities

An American biotech firm that develops and produces synthetic DNA has established an international presence by purchasing an Israeli genetic design software company. Twist Bioscience Corporation (San Francisco, CA, USA), a company specializing in rapid, high-quality DNA synthesis, announced that Genome Compiler Corporation... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.